EDRN Biomarker Reference Laboratory

National Cancer Institute, Frederick MD

Investigators

Abstract

The CPDR BRL will perform analytical validation of biomarkers and biomarker assays developed by other EDRN investigators and by other investigators. This includes Mass Spectrometry-based Detection of Multiple Candidate Biomarkers from Target Cells Enriched by Laser Capture Microdissection; Validation of Prostate Cancer Biomarkers Using the CPDR ERG Monoclonal Antibody (CPDR ERG-MAb) as a Paradigm; and Development and Testing of New Monoclonal Antibodies for Prostate Cancer Diagnosis and Prognosis Focusing on ETS family of oncoproteins and new prostate cancer markers.